RNS Number: 2852 S Hikma Pharmaceuticals Plc 07 July 2020 Hikma Finance USA LLC. Hikma Finance USA LLC announces today that it has published an offering circular dated 7 July 2020 in connection with the issuance of US $500,000,000 3.250 per cent. Guaranteed Notes due 2025 guaranteed by Hikma Pharmaceuticals PLC, Al Jazeerah Pharmaceutical Industries Ltd, Arab...
RNS Number: 1308 R Hikma Pharmaceuticals Plc 25 June 2020 TR-1: S tandard form for notification of major holdings. LONDON, 25 June 2020- Hikma Pharmaceuticals PLC announces as follows:. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1135 R Hikma Pharmaceuticals Plc 25 June 2020 Jochen Gann Resigns from the Board of Hikma. London, 25 June 2020- Hikma Pharmaceuticals PLC announces that, following the disposal of shares by Boehringer Ingelheim Invest GmbH and in accordance with the shareholder agreement between Hikma and BI, that Dr. Jochen Gann has resigned his directorship of...
RNS Number: 8326 Q FTSE Russell 23 June 2020. Hikma Pharmaceuticals: Shares in Issue and Investability Weight Change Changes in FTSE UK Index Series. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 8100 Q Hikma Pharmaceuticals Plc 23 June 2020 TR-1: S tandard form for notification of major holdings. LONDON, 23 June 2020- Hikma Pharmaceuticals PLC announces as follows:. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 7668 Q Hikma Pharmaceuticals Plc 23 June 2020 23 June 2020. Transaction in Own Shares and Total Voting Rights and Capital. Further to the announcements by Hikma and Boehringer Ingelheim Invest GmbH on 22 nd June 2020, Hikma today announces the Company has entered into arrangements to buy back approximately 12.8 million ordinary shares currently...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR FORM AN...
RNS Number: 7089 Q Hikma Pharmaceuticals Plc 22 June 2020 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN, AUSTRALIA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Buy back of up to approximately £295 million of shares from Boehringer Ingelheim. Concurrently with the...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR FORM AN...
RNS Number: 6675 Q Hikma Pharmaceuticals Plc 22 June 2020 Hikma Pharmaceuticals PLC. Notification and public disclosure of transactions by persons discharging managerial responsibilities. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 6672 Q Hikma Pharmaceuticals Plc 22 June 2020 Hikma Pharmaceuticals PLC. Notification and public disclosure of transactions by persons discharging managerial responsibilities. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 6668 Q Hikma Pharmaceuticals Plc 22 June 2020 Hikma Pharmaceuticals PLC. Notification and public disclosure of transactions by persons discharging managerial responsibilities. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 6755 O Hikma Pharmaceuticals Plc 02 June 2020. LONDON, 2 June 2020- In accordance with the UK Financial Conduct Authority's DTR 5.6. 1, Hikma Pharmaceuticals PLC notifies the market that as at 31 May 2020, its share capital consists of 243,169,353 ordinary shares with voting rights. Headquartered in the UK, we are a global company with a local presence...
Hikma Pharmaceuticals Plc (HIK.L) Announced that its wholly owned US subsidiary Hikma Pharmaceuticals USA Inc. has received approval from the US Food and Drug Administration (FDA) for its Icosapent Ethyl Capsules, 1 gm, the generic equivalent to Vascepa. In March 2020, the US District Court for the District of Nevada invalidated six key Vascepa patents owned by Amarin. The District Court decision is currently being appealed. #HIK
RNS Number: 7388 N Hikma Pharmaceuticals Plc 22 May 2020 London, May 22, 2020- Hikma Pharmaceuticals PLC, the multinational generic pharmaceutical company, today announces that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA Inc. has received approval from the US Food and Drug Administration for its Icosapent Ethyl Capsules, 1 gm, the generic...
RNS Number: 5260 N Hikma Pharmaceuticals Plc 20 May 2020. LONDON, 20 May 2020: Hikma Pharmaceuticals PLC announces that the following Persons Discharging Managerial Responsibility have received shares as a result of the vesting of their conditional share awards on 16 May 2018 under the 2014 Executive Incentive Plan Element B which was completed on 19 May...
RNS Number: 8074 M Hikma Pharmaceuticals Plc 13 May 2020 Hikma Pharmaceuticals PLC. Notification and public disclosure of transactions by persons discharging managerial responsibilities. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 6293 L Hikma Pharmaceuticals Plc 01 May 2020. LONDON, 1 May 2020- In accordance with the UK Financial Conduct Authority's DTR 5.6. 1, Hikma Pharmaceuticals PLC notifies the market that as at 30 April 2020, its share capital consists of 242,543,355 ordinary shares with voting rights. Headquartered in the UK, we are a global company with a local presence...
LONDON, 30 April 2020 Hikma Pharmaceuticals PLC announces its Annual General Meeting, held at 22 Regent Road, Surbiton KT5 8 NL on 30 April 2020 commenced at 10:00 am. All resolutions were duly passed by shareholders by way of a poll. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling.
RNS Number: 3942 L Hikma Pharmaceuticals Plc 30 April 2020 Hikma appoints Douglas Hurt as Director. London, 30 April 2020- Hikma Pharmaceuticals PLC announces the appointment of Douglas Hurt as an independent non-executive director effective 1 May 2020. Over the course of 2020, Douglas will assume responsibility for chairing the Audit Committee..
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    241.47M

Company Profile

Hikma is an international pharmaceutical company conducting operations through three businesses: generic pharmaceuticals, branded pharmaceuticals and injectable pharmaceuticals. The company sells 113 branded and non-branded generic pharmaceutical products in 34 countries worldwide. The majority of Hikma's operations are in the United States, the Middle East and North Africa Region and Europe.

Classification

Market Indices-
Watchlist